Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NovaBay Pharmaceuticals (NBY) Enterprise Value (2016 - 2025)

Historic Enterprise Value for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to -$2.3 million.

  • NovaBay Pharmaceuticals' Enterprise Value fell 19755.15% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.3 million, marking a year-over-year decrease of 19755.15%. This contributed to the annual value of -$430000.0 for FY2024, which is 8529.41% up from last year.
  • Per NovaBay Pharmaceuticals' latest filing, its Enterprise Value stood at -$2.3 million for Q3 2025, which was down 19755.15% from -$5.3 million recorded in Q2 2025.
  • NovaBay Pharmaceuticals' Enterprise Value's 5-year high stood at -$430000.0 during Q4 2024, with a 5-year trough of -$10.5 million in Q1 2021.
  • Moreover, its 5-year median value for Enterprise Value was -$3.9 million (2022), whereas its average is -$4.8 million.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' Enterprise Value skyrocketed by 8529.41% in 2024 and then plummeted by 61158.46% in 2025.
  • Over the past 5 years, NovaBay Pharmaceuticals' Enterprise Value (Quarter) stood at -$7.5 million in 2021, then rose by 28.54% to -$5.4 million in 2022, then soared by 45.47% to -$2.9 million in 2023, then surged by 85.29% to -$430000.0 in 2024, then crashed by 436.98% to -$2.3 million in 2025.
  • Its Enterprise Value stands at -$2.3 million for Q3 2025, versus -$5.3 million for Q2 2025 and -$8.5 million for Q1 2025.